Characteristics of patients with Alzheimer's disease who switch to rivastigmine transdermal patches in routine clinical practice

Patient Preference and Adherence

Volumn 7, Issue , 2013, Pages 47-54

  López Pousa, Secundino ^a   Arranz, Francisco Javier ^b  

^a Hospital de Santa Caterina   (Spain)

^b ESTEVE   (Spain)

Author keywords

Adherence; Alzheimer's disease; Cholinesterase inhibitors; Donepezil; Galantamine; Rivastigmine transdermal patches

Indexed keywords

CHOLINESTERASE INHIBITOR; DONEPEZIL; GALANTAMINE; MEMANTINE; RIVASTIGMINE;

ALZHEIMER DISEASE; AMBULATORY CARE; ARTICLE; CAREGIVER; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL PRACTICE; COMORBIDITY; DEMOGRAPHY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EDUCATIONAL STATUS; FEMALE; HUMAN; INFORMATION PROCESSING; MALE; NEUROLOGIST; OBSERVATIONAL STUDY; PATIENT COMPLIANCE; RETROSPECTIVE STUDY; STEP WISE MULTIPLE REGRESSION; TRANSDERMAL PATCH;

EID: 84872814761     PISSN: None     EISSN: 1177889X     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Popp J, Arlt S. Pharmacological treatment of dementia and mild cognitive impairment due to Alzheimer's disease. Curr Opin Psychiatry. 2011;24:556-561.
2. Farlow MR, Grossberg GT, Meng X, Olin J, Somogyi M. Rivastigmine transdermal patch and capsule in Alzheimer's disease: infuence of disease stage on response to therapy. Int J Geriatr Psychiatry. 2011;26: 1236-1243.
3. Lee JH, Sevigny J. Effects of body weight on tolerability of rivastigmine transdermal patch: a post-hoc analysis of a double-blind trial in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 2011;25: 58-62.
4. Gauthier S, Juby A, Rehel B, Schecter R. EXACT: rivastigmine improves the high prevalence of attention defcits and mood and behaviour symptoms in Alzheimer's disease. Int J Clin Pract. 2007;61: 886-895.
5. Winblad B, Machado JC. Use of rivastigmine transdermal patch in the treatment of Alzheimer's disease. Expert Opin Drug Deliv. 2008;5: 1377-1386.
6. Cummings J, Winblad B. A rivastigmine patch for the treatment of Alzheimer's disease and Parkinson's disease dementia. Expert Rev Neurother. 2007;7:1457-1463.
7. Molinuevo JL, Arranz FJ. Impact of transdermal drug delivery on treatment adherence in patients with Alzheimer's disease. Expert Rev Neurother. 2012;12:31-37.
8. Molinuevo JL, Arranz FJ. Assessment of the strategies to improve therapeutic compliance in routine clinical practice in noncompliant patients with Alzheimer-type dementia. Rev Neurol. 2012;54:65-73.
9. Blesa R, Ballard C, Orgogozo JM, Lane R, Thomas SK. Caregiver preference for rivastigmine patches versus capsules for the treatment of Alzheimer disease. Neurology. 2007;69(4 Suppl 1):S23-S28.
10. Sevilla C, Jiménez-Caballero PE, Alfonso V. Orally disintegrating donepezil: are the main caregivers of patients with Alzheimer's disease more satisfed with this formulation of donepezil than with the traditional one? Rev Neurol. 2009;49:451-457.
11. Cummings J, Froelich L, Black SE, et al. Randomized, double-blind, parallel-group, 48-week study for effcacy and safety of a higher-dose rivastigmine patch (15 versus 10 cm2) in Alzheimer's disease. Dement Geriatr Cogn Disord. 2012;33:341-353.
12. Bullock R, Touchon J, Bergman H, et al. Rivastigmine and donepezil treatment in moderate to moderately-severe Alzheimer's disease over a 2-year period. Curr Med Res Opin. 2005;21:1317-1327.
13. Lockhart IA, Mitchell SA, Kelly S. Safety and tolerability of donepezil, rivastigmine and galantamine for patients with Alzheimer's disease: systematic review of the 'real-world' evidence. Dement Geriatr Cogn Disord. 2009;28:389-403.
14. Winblad B, Cummings J, Andreasen N, et al. A six-month double-blind, randomized, placebo-controlled study of a transdermal patch in Alzheimer's disease - rivastigmine patch versus capsule. Int J Geriatr Psychiatry. 2007;22:456-467.
15. Guay DR. Rivastigmine transdermal patch: role in the management of Alzheimer's disease. Consult Pharm. 2008;23:598-609.
16. Monod S, Rochat S, Gold G, Büla C. Review in geriatric medicine. Rev Med Suisse. 2009;5:19-24. French.
17. Bassil N, Grossberg GT. Novel regimens and delivery systems in the pharmacological treatment of Alzheimer's disease. CNS Drugs. 2009; 23:293-307.